Compare Prudential Financial Inc (PRU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Prudential Financial Inc trades at $113.09 (market cap $39.17B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Prudential Financial Inc is far larger — about 3.9× State Street SPDR S&P Biotech ETF's market cap, and Prudential Financial Inc pays a 4.93% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential Financial Inc for 145 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| PRU | XBI | |
|---|---|---|
Market Cap | $39.17B | $10.11B |
Volume | 1,436,917 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $125.13 | $169.55 |
52-Week Low | $92.00 | $104.99 |
Typical Hold Time | 145 Days | 38 Days |
Enterprise Value | $67.95B | — |
Dividend Yield | 4.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $113.53, up 1.04% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates solid fundamentals with a P/E of 10.29 and ROE of 12.46%, while recent earnings show two consecutive beats. Strategic moves include the Alexforbes stake sale and rebranding to Prudential Wealth Advisors, reflecting focus on core operations.
PRU presents a value opportunity with attractive valuation metrics, though analyst consensus is cautious with 67.57% hold ratings. Key risks include interest rate sensitivity and execution of the $3B capital rotation plan. The stock trades above the $105.67 consensus target, suggesting limited near-term upside despite strong annuity market positioning.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
